Want to use our logo?

Download the ICS Branding Pack

ICS Background

Dr Yoshihisa Matsukawa
Department of Urology, Nagoya University Graduate School of Medicine, Japan

ICS 2019

Podium Short Oral Session 11 Male Lower Urinary Tract Symptoms 1 226 Comparison of long-term effects of tadalafil and silodosin on storage and voiding function in male patients with detrusor underactivity induced by benign prostatic hyperplasia

ICS 2017

Podium Short Oral Session 15 Male Lower Urinary Tract Dysfunction 275 Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia, based on a urodynamic study

ICS 2016

Open Discussion ePoster Session 7 Open Discussion ePosters 127 Contributing factors to failure of improvement of subjective symptoms after mirabegron administration in female patients with an overactive bladder

ICS 2015

Podium Session 19 What's New in Bladder Outlet Obstruction 253 The effects of withdrawing the alpha-1 blocker from alpha-1 blocker plus 5-alpha-reductase inhibitor combination therapy on patients with benign prostatic hyperplasia from the perspective of urodynamics study

Podium Short Oral Session 34 Pharmacotherapy for Overactive Bladder 489 Objective efficacy of mirabegron on storage and voiding function in patients with overactive bladder that is unresponsive to antimuscarinic treatment, based on a urodynamic study

ICS 2014

Podium Poster Session 42 Overview of Benign Prostatic Obstruction 658 The relationship between testosterone secretion and the improvement of bladder outlet obstruction by alpha1-blocker in men with benign prostatic hyperplasia

ICS 2013

Non Discussion Poster Session 34 377 What are the factors that can simply estimate the therapeutic effects of 5a reductase inhibitors in patients with male LUTS?

Non Discussion Poster Session 34 534 Slow stream is essential for poor responder in a1-adrenoceptor therapy to storage symptoms with benign prostatic hyperplasia

Non Discussion Abstract Session 35 Read By Title 750 Significance of residual urine in drug therapy for patients with benign prostatic hyperplasia accompanied by overactive bladder (BPH/OAB)

Non Discussion Abstract Session 35 Read By Title 753 Objective efficacy of mirabegron on storage and voiding function in patients with overactive bladders based on a urodynamic study

ICS 2012

Non Discussion Poster Session 31 445 Is combination therapy with an anticholinergic agent and an a1-adrenoceptor antagonist effective as first-line treatment for patients with benign prostatic hyperplasia complicated by an overactive bladder? A randomized, prospective, comparative, urodynamic study

ICS 2011

Non Discussion Poster Session 29 291 Long-term efficacy of Silodosin on the lower urinary tract function in patients with benign prostatic hyperplasia according to prostate size: prospective investigation using pressure-flow study

Non Discussion Abstract Session 31 Read by Title 645 Frequency and bother of post-micturition symptoms in patients with benign prostatic hyperplasia, and their fluctuation by Tamsulosin treatment

Podium Poster Session 6 Male Lower Urinary Tract and Surgery 67 What is the cause of the poor improvement cases of International Prostate Symptom Score after Silodosin administration in LUTS with BPH? ~Prospective investigation using a pressure-flow study~

ICS 2009

Non Discussion Poster Session 32 494 Stimulations of autonomic receptors cause release of prostaglandin E2 (PGE2) from rat bladder

Podium Poster Session 9 Male Incontinence 97 DECLINED URETHRAL SPHINCTER FUNCTION RELATED TO AGING COMTRIBUTES TO URINARY INCONTINENCE AFTER RADICAL PROSTATECTOMY

ICS 2007

Non Discussion Poster Session 17 294 De-novo detrusor underactivity following laparoscopic radical prostatectomy

Yoshihisa Matsukawa

Committee Member

Qualifications:PhD
Privacy:
You must be logged in to view this contact
Sign-in to ICS

Dr Yoshihisa Matsukawa declared on the Monday 28th January 2019 that they did not have any existing or known future financial relationships or affiliations to disclose (NONE).

UP TO DATE!